- Home
- FOUR vs VRNA Comparison
FOUR vs VRNA Comparison
Compare FOUR & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOUR
- VRNA
- Stock Information
- Founded
- FOUR 1999
- VRNA 2005
- Country
- FOUR United States
- VRNA United Kingdom
- Employees
- FOUR N/A
- VRNA N/A
- Industry
- FOUR Business Services
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- FOUR Consumer Discretionary
- VRNA Health Care
- Exchange
- FOUR Nasdaq
- VRNA Nasdaq
- Market Cap
- FOUR 6.9B
- VRNA 8.3B
- IPO Year
- FOUR 2020
- VRNA 2017
- Fundamental
- Price
- FOUR $85.97
- VRNA $106.37
- Analyst Decision
- FOUR Buy
- VRNA Buy
- Analyst Count
- FOUR 19
- VRNA 11
- Target Price
- FOUR $113.28
- VRNA $114.10
- AVG Volume (30 Days)
- FOUR 1.3M
- VRNA 1.3M
- Earning Date
- FOUR 11-11-2025
- VRNA 11-03-2025
- Dividend Yield
- FOUR N/A
- VRNA N/A
- EPS Growth
- FOUR 55.45
- VRNA N/A
- EPS
- FOUR 2.56
- VRNA N/A
- Revenue
- FOUR $3,610,700,000.00
- VRNA $221,673,000.00
- Revenue This Year
- FOUR $28.69
- VRNA $896.59
- Revenue Next Year
- FOUR $24.06
- VRNA $77.56
- P/E Ratio
- FOUR $33.52
- VRNA N/A
- Revenue Growth
- FOUR 23.86
- VRNA N/A
- 52 Week Low
- FOUR $68.09
- VRNA $27.54
- 52 Week High
- FOUR $127.50
- VRNA $106.45
- Technical
- Relative Strength Index (RSI)
- FOUR 38.35
- VRNA 71.51
- Support Level
- FOUR $85.25
- VRNA $106.15
- Resistance Level
- FOUR $88.51
- VRNA $106.42
- Average True Range (ATR)
- FOUR 2.15
- VRNA 0.20
- MACD
- FOUR 0.06
- VRNA -0.16
- Stochastic Oscillator
- FOUR 9.88
- VRNA 90.91
About FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.